文献速递炎症性肠病胃肠动力与功能性疾病

系统综述与Meta分析:168项粪菌移植临床研究中供体特征、操作流程与结局的回顾

Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation.
PubMed 文献 · Aliment Pharmacol Ther · 2019-01-09

该系统综述纳入168项粪菌移植临床研究,评估供体特征、操作流程与临床结局。CDI最终治愈率为95.6%(95%CI 93.9%-97.1%),UC和CD最终缓解率分别为39.6%(95%CI 25.4%-54.6%)和47.5%(95%CI 29.4%-65.8%)。供体筛选、应用与结局存在异质性,数据可促进FMT方案标准化。

要点

  • CDI最终治愈率95.6%(95%CI 93.9%-97.1%),UC和CD最终缓解率分别为39.6%(25.4%-54.6%)和47.5%(29.4%-65.8%)。
  • CDI治愈率及CD、UC最终缓解率在不同FMT给药途径间相当。
  • 总体不良事件发生率<1%,多为胃肠道相关,不同给药途径或适应症间无显著差异。

核心结论

  • 在评估供体特征与FMT疗效的系统综述中,观察到供体选择、应用和结局存在异质性,这些数据可促进不同疾病FMT方案的标准化。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE和EMBASE截至2018年8月29日发表的FMT研究,纳入168项含FMT供体信息的临床研究。

主要发现

  • 共报告1513名供体特征,58%为男性,平均年龄34.3岁,平均体重指数21.6。
  • 亚洲供体较西方供体年轻(平均年龄30.7岁 vs 32.9岁,P=0.00075)。
  • 不足50%的研究对供体进行了可传播病原体筛查。
  • CDI最终治愈率为95.6%(95%CI 93.9%-97.1%),UC和CD最终缓解率分别为39.6%(95%CI 25.4%-54.6%)和47.5%(95%CI 29.4%-65.8%)。
  • 总体不良事件发生率<1%,多为胃肠道相关;不良事件率在不同FMT给药途径或适应症间无显著差异。

关键数值与推荐

  • FMT最常用于CDI(n=108)和炎症性肠病(n=31)。
  • CDI治愈率及CD、UC最终缓解率在所有FMT给药途径间相当。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Faecal microbiota transplantation (FMT) is effective for Clostridium difficile infections (CDI) refractory to standard treatment and is being studied in other diseases. AIM: To evaluate donor characteristics, procedures and clinical outcomes of FMT. METHODS: We systematically reviewed FMT studies published up to 29 August 2018 using MEDLINE (R) and EMBASE and identified clinical studies with FMT donor information. We reported data on donor characteristics, screening criteria, administration, clinical outcomes and adverse events. RESULTS: Among 5267 reports, 239 full-text articles were screened and 168 articles were included. FMT was performed commonly for CDI (n = 108) and inflammatory bowel disease (IBD) (n = 31). We reported characteristics of 1513 donors [58% male; mean age, 34.3 years; mean body mass index, 21.6]. Donors in Asia were younger than the West (mean age 30.7 vs 32.9, P = 0.00075). Less than 50% of studies screened donors for transmittable pathogens. Final cure rate for CDI was 95.6% (95% confidence interval [CI], 93.9%-97.1%) and final remission rates for ulcerative colitis (UC) and Crohn's disease (CD) were 39.6% (95% CI, 25.4%-54.6%) and 47.5% (95% CI, 29.4%-65.8%), respectively. Cure rates in CDI and final remission rates for CD and UC were comparable across all routes of FMT administration. Overall adverse event incidence was <1%, mostly GI-related. Adverse event rates did not differ significantly between routes of FMT administration or indication. CONCLUSIONS: In a systematic review assessing donor characteristics and FMT efficacy, we observed heterogeneity in donor selection, application and outcomes of FMT. These data can facilitate standardisation of FMT protocols for various diseases.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lai CY, Sung J, Cheng F, et al. Systematic review with meta-analysis: review of donor features, procedures and outcomes in 168 clinical studies of faecal microbiota transplantation. Aliment Pharmacol Ther. 2019. PMID: 30628108. doi:10.1111/apt.15116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。